4.5 mg
Trade Name
Mylotarg
Powder for concentrate for solution for infusion
Request Type
Registration
Drug Type
Biological Drug
Approval Date
SFDA Approved Use
Combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients aged 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).